(IDYA) IDEAYA Biosciences, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(IDYA) IDEAYA Biosciences, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This IDEAYA Biosciences, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is useful for strategy, portfolio review, and capital allocation, and this page already shows a real preview of the actual analysis. Buy the full version to get the complete ready-to-use report.
Stars
IDE196, PKC inhibitor, Phase I/II
IDE196, also known as darovasertib, is IDEAYA Biosciences, Inc.'s lead in-house asset and the most advanced program at Phase I/II. It targets GNAQ/GNA11 mutations, which drive more than 90% of uveal melanoma cases, and that gives it a clear edge in precision oncology. In BCG terms, it fits as a Star because it is in a fast-growing niche and IDEAYA keeps pushing it deeper into late-stage development.
IDE397, MAT2A inhibitor, Phase I
IDE397 is IDEAYA Biosciences, Inc.’s first-in-class MAT2A inhibitor for MTAP-deleted solid tumors, a biomarker seen in about 15% to 25% of cancers. Its Phase I status puts it in a high-growth slot, since MTAP loss opens a large precision-oncology market. As one of IDEAYA’s lead clinical assets, it is a top-priority value driver.
MTAP-deletion synthetic lethality franchise
IDEAYA’s MTAP-deletion synthetic lethality franchise is a core growth engine, with IDE397 as the lead asset and a broad path across multiple solid tumors. The company reported $748.5M in cash, cash equivalents, and marketable securities as of Q1 2024, giving it room to push this platform while clinical data stay strong. That supports a scalable leadership case, not a niche bet.
GNAQ and GNA11 biomarker-led oncology franchise
IDEAYA Biosciences, Inc. built its PKC program around GNAQ and GNA11-driven tumors, mainly uveal melanoma, where these mutations appear in about 80% to 90% of cases. That tight biomarker filter shrinks the addressable pool, but it makes patient matching cleaner and can lift response rates if adoption keeps rising.
In IDEAYA’s darovasertib program, the biomarker-led design has already shown strong clinical signal in genetically defined disease, which is what a Star needs in BCG terms. The franchise looks most attractive if it keeps converting a small but high-need population into repeatable use.
For investors, the key test is scale, not science: high target precision, clear mutation testing, and better outcomes can support growth even in a niche market. If penetration deepens in uveal melanoma and related GNAQ/GNA11 tumors, this could stay a Star.
- 80%-90% mutation rate in uveal melanoma
- Clear biomarker makes targeting easier
- Niche market, but high precision
- Star case depends on adoption growth
Clinical precision-oncology platform
IDEAYA Biosciences, Inc. treats its clinical precision-oncology platform as a Star because its synthetic lethality and biomarker selection engine can keep spawning new oncology programs, not just one asset. That matters in a pipeline-led model: each hit can feed the next wave of trials and widen the addressable market. In 2025, the platform still underpins multiple clinical-stage bets, so its growth option is bigger than any single drug.
- Drives repeated target discovery
- Uses biomarker-led patient selection
- Supports multiple pipeline programs
- Fits a high-growth Star profile
IDEAYA’s Star Assets: Darovasertib and IDE397 Keep Growth in Focus
IDEAYA Biosciences, Inc. keeps its Stars in darovasertib and IDE397: both are biomarker-led, clinical-stage, and tied to large unmet needs in precision oncology. Darovasertib targets GNAQ/GNA11 uveal melanoma, while IDE397 targets MTAP-deleted tumors across a broader solid-tumor base. These programs still look like growth drivers, not cash cows.
| Star asset | Stage | Why it fits |
|---|---|---|
| Darovasertib | Phase I/II | Strong biomarker fit |
| IDE397 | Phase I | Broad MTAP market |
What is included in the product
Detailed Word Document
IDEAYA’s BCG Matrix maps its oncology pipeline across Stars, Question Marks, Cash Cows, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page IDEAYA Biosciences BCG Matrix that clarifies pipeline priorities for fast strategic decisions
Reference Sources
Provides a credible source trail for IDEAYA Biosciences, helping investors verify assumptions quickly and make decisions with greater confidence.
Cash Cows
Pfizer partnership, metastatic uveal melanoma and skin melanoma
IDEAYA Biosciences, Inc.'s Pfizer partnership on metastatic uveal melanoma, skin melanoma, and other solid tumors helps fund development and supply, so it lowers IDEAYA Biosciences, Inc.'s cash burn. That makes it a cash cow in BCG terms: the asset can keep generating value while Pfizer shares trial costs and execution risk.
GSK strategic alliance
IDEAYA’s strategic alliance with GlaxoSmithKline works like a cash-flow buffer: it can bring non-dilutive funding, milestone payments, and shared development costs, without IDEAYA needing a marketed product. In 2025, that matters because IDEAYA still had no product revenue, so partner-backed capital helps reduce dilution and supports pipeline spending.
Cancer Research UK and University of Manchester collaboration
IDEAYA Biosciences, Inc.'s Cancer Research UK and University of Manchester tie-up fits Cash Cows because it offloads early PARG inhibitor discovery to outside researchers. That can cut IDEAYA's internal lab spend and preserve capital for later-stage programs. The tradeoff is modest direct revenue, but it helps build a lower-cost pipeline.
Partner-funded clinical supply model
IDEAYA Biosciences, Inc.’s partner-funded clinical supply model shifts drug-manufacturing and trial-supply costs onto collaborators, so IDEAYA keeps more cash for R&D. In precommercial biotech, that works like a cash cow because partner support lowers burn while the company still advances programs. This structure improves capital efficiency and helps preserve runway through 2025 filings and 2026 development spend.
- Partners fund part of clinical supply costs
- Lower burn, better cash preservation
- More capital for pipeline development
Non-dilutive collaboration income stream
IDEAYA Biosciences, Inc. leans on partner-funded deals, not product sales, so upfront cash, milestone payments, and shared R&D costs act like its cash cow. With no approved drugs yet, this is its closest mature cash-generating stream and helps fund oncology programs without heavy dilution. That matters because every deal can extend runway before launch revenue exists.
- Upfronts fund early work
- Milestones add non-dilutive cash
- Cost-sharing lowers burn
- No approved drugs yet
IDEAYA’s Cash Cow: Partner-Funded R&D
IDEAYA Biosciences, Inc. has no approved drugs in 2025-2026, so its Cash Cows are partner deals, not product sales. Pfizer, GlaxoSmithKline, and Cancer Research UK/University of Manchester help fund R&D through upfronts, milestones, and shared trial costs, which cuts burn and stretches runway. That makes partner-funded collaboration the closest steady cash source for IDEAYA Biosciences, Inc.
| Metric | 2025-2026 |
|---|---|
| Approved products | 0 |
| Named strategic partners | 3 |
| Funding effect | Lower cash burn |
Get Your Copy
IDEAYA Biosciences, Inc. Reference Sources
You’re previewing the exact IDEAYA Biosciences, Inc. BCG Matrix report you’ll receive after purchase. The file includes the same professional formatting, analysis, and structure shown here—no demo content or hidden changes. Once purchased, you’ll get the full version instantly for download, editing, or presentation. What you see is what you get.
Dogs
0 approved products
IDEAYA Biosciences has 0 approved products and no commercial sales, so the Dog quadrant is effectively empty. In 2025, the Company remained clinical-stage, with value tied to pipeline assets like darovasertib rather than an installed brand. So there is no true revenue dog to classify or divest.
0 marketed oncology brands
IDEAYA Biosciences, Inc. has 0 marketed oncology brands, so there is no commercial product base to trail in a mature market. In 2025, it still had no routine product sales, which means this BCG Dogs bucket does not fit the classic low-growth, low-share profile.
With no launch yet, IDEAYA Biosciences, Inc. avoids the drag of an installed brand losing share. The company is still pre-commercial, so the key numbers are pipeline and cash, not marketed-brand sales.
0 direct product revenue
IDEAYA Biosciences had $0 direct product revenue in its latest reported fiscal year, so its value still comes from pipeline programs and partnerships, not sales. There is no legacy product cash flow to cut or divest, which means this is not a "dog" in the classic BCG sense. The company is still pre-commercial, with cash tied to R&D and deal milestones, not a product line.
0 mature commercial franchise
IDEAYA Biosciences, Inc. still has 0 approved products and no mature commercial franchise, so there is no low-growth cash cow to defend. With 2025 revenue at $0 and no broad sales force in place, this “Dogs” bucket is effectively empty. In BCG terms, there is no cash-trap product unit here.
- No approved therapy
- 2025 revenue: $0
- No commercial sales base
- No cash-cow asset
0 dividend or buyback cash engine
IDEAYA Biosciences, Inc. showed a 0 dividend and 0 buyback cash return profile in FY2025, which fits a clinical-stage biotech that keeps capital inside research and development. It is not a mature cash-distribution company, so the dog quadrant is structurally absent.
- 0 dividend payout in FY2025
- 0 share repurchases disclosed
- Cash stayed focused on R and D
- No steady product cash to return
That matters because IDEAYA’s 2025 spending priority was pipeline buildout, not shareholder cash yield. In BCG terms, its low payout and reinvestment profile signal growth-stage risk, not a “dog” cash drag.
No Dogs, Just Pipeline and Cash Preservation
IDEAYA Biosciences, Inc. has no approved products, no commercial sales, and FY2025 revenue of $0, so the Dogs quadrant is effectively empty. With no legacy brand to defend or divest, the business stays focused on pipeline R&D and cash preservation. There is no true low-share, low-growth product unit to classify as a dog.
| Metric | FY2025 |
|---|---|
| Approved products | 0 |
| Revenue | $0 |
| Commercial sales | 0 |
Question Marks
PARG inhibitor, preclinical to early-stage
IDEAYA Biosciences, Inc.’s PARG inhibitor is a preclinical-to-early-stage synthetic lethality bet aimed at biomarker-defined tumors, so it fits the Question Mark bucket. The asset still lacks clinical proof, so market share is uncertain even if the biology works. That mix of high upside and high failure risk is classic Question Mark behavior.
Pol Theta inhibitor, BRCA and HRD tumors
IDEAYA Biosciences, Inc.’s Pol Theta inhibitor targets BRCA and other homologous recombination deficiency tumors, a large and biologically appealing market, with HRD seen in about 20% to 25% of solid tumors. But the program is still early, so clinical proof is limited and the value case is not yet de-risked. It stays a Question Mark until stronger efficacy and safety data can show it can become a Star.
WRN inhibitor, MSI-H tumors
IDEAYA Biosciences, Inc. is advancing a WRN inhibitor for microsatellite instability-high, or MSI-H, tumors, a biomarker found in about 3% to 5% of solid tumors. The target is clear, but the asset is still in development, so it has no commercial proof yet. Until clinical data show durable response and safety, this program stays in question-mark territory.
Additional synthetic lethality discovery programs
IDEAYA Biosciences, Inc. keeps pushing beyond its lead assets by adding new synthetic lethality targets, and that gives it pipeline optionality. These programs fit the question-mark box because they are still unproven until human data show response and durability. They also draw on R and D capital before payback is clear.
- High upside, low proof.
- R and D spend stays front-loaded.
- Success depends on trial readouts.
New biomarker-defined oncology indications
IDEAYA Biosciences, Inc. treats new biomarker-defined oncology indications as a growth bet: each new genetically selected tumor group can open a large market, but share stays at 0% until Phase 1/2 data show real clinical traction. That is why this sits in the BCG Question Marks bucket: high upside, but still unproven.
- High growth, no current share
- Clinical data drives adoption
- Execution risk stays elevated
IDEAYA’s Early Bets Target Big Biomarker Markets
IDEAYA Biosciences, Inc.’s question marks are still early, high-upside bets with no commercial share yet. PARG, POLQ, and WRN programs target biomarker-defined tumors, but each still needs Phase 1/2 proof before value can re-rate. MSI-H tumors are only about 3% to 5% of solid tumors, while HRD is about 20% to 25%.
| Program | State | Key number |
|---|---|---|
| PARG | Early | No clinical proof |
| POLQ | Early | HRD 20% to 25% |
| WRN | Early | MSI-H 3% to 5% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.